ALB and Crohn disease: As discussed earlier, early intervention in Crohn’s disease has become increasingly encouraged, and, as such, it should be pushed in order to optimize initial treatment response through monitoring for immunogenicity, or through the idea of neutralizing antidrug antibodies causing the acceleration of drug clearance, along with measurement of patient factors, such as body size and serum albumin concentration, to account for variable pharmacokinetic properties between patients [79].